To include your compound in the COVID-19 Resource Center, submit it here.

Emerging Companies

Bolt’s myeloid twist on ADCs charged up with $93.5M series C

Bolt’s $93.5 million series C round will enable the Stanford spinout to clinically test whether its myeloid-activating antibody conjugate can provide durable treatment to a broad swath of HER2-positive solid tumor patients. Led by Sofinnova...

Engrail aims to build CNS pipeline by improving upon deprioritized assets

With a $32 million series A round from Nan Fung, Engrail expects to advance its first CNS program into the clinic by 1Q21 as it builds out a pipeline of neuroscience drugs via deals for...

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s...

Artiva launches with $78M to develop Korean biotech’s NK cell programs outside Asia

A U.S. investor syndicate and management team have set up Artiva, bringing to San Diego allogeneic natural killer cell technology from South Korean company GC LabCell -- including one program due to enter the clinic...

Sana’s quest to usher in next generation of cell, gene therapies

With $700 million in its coffers, Sana has broad goals to develop cell and gene therapies that address a wide swath of diseases, with its sights set beyond cancer and rare diseases. While the biotech...

Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

Simcha emerged Wednesday with $25 million in series A funding to bring its lead product, a variant of IL-18 designed to thwart a resistance mechanism in tumors, through Phase I testing. The corporate venture fund...

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

After incubating in Frazier for a year and half, Lassen emerged from stealth Wednesday with a preclinical program targeting the IL-11 receptor that could be applied to both fibrosis and cancer and enough funds to...

Lightspeed, Klausner back Stanford cell therapy spinout Orca in new $192M round

With the completion of a new $192 million series D round, Stanford spinout Orca Bio has now raised nearly $300 million to develop and manufacture allogeneic cell therapies that use controlled formulations designed to reduce...

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next...

With $50M from Versant, Lycia takes targeted degradation outside the cell

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into...

Epsilogen: co-opting IgE antibodies against cancer

Epsilogen is taking a long overlooked isotype of human antibodies -- the IgE class -- and leveraging their high affinity for immune effector cells to seek out and destroy solid tumors. “What we are doing...

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively...

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Monte Rosa has built a library of small molecule protein degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline,...